ECM
OLMA icon

Endurant Capital Management’s Olema Pharmaceuticals OLMA Stock Holding History

Endurant Capital Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-58,573
Closed -$723K – 46
2023
Q3 		$723K Buy
58,573
+18,389
+46% +$187K 0.65% 36
2023
Q2 		$363K Buy
+40,184
New +$243K 0.32% 33

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Endurant Capital Management's OLMA Position: Q4 2023 in Review

Endurant Capital Management sold out of Olema Pharmaceuticals (OLMA) in Q4 2023, closing a stake of 58,573 shares — an estimated $723K sold.

Endurant Capital Management first reported a position in OLMA in Q2 2023 and held it in 2 quarters. The position peaked at $723K in Q3 2023. 113 funds tracked by Wall St. Rank hold OLMA as of Q4 2023.

  • Endurant Capital Management reported no remaining Olema Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 58,573 Olema Pharmaceuticals shares in Q4 2023, an estimated $723K.
  • Endurant Capital Management first reported a position in Olema Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Endurant Capital Management's Olema Pharmaceuticals position peaked at $723K in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.